Spero Therapeutics, Inc. (SPRO) Operating margin 2016–2025
Spero Therapeutics, Inc. (SPRO) operating margin by fiscal year — reported operating income divided by reported revenue.
50.2%FY2025 · since FY2016: -9916.7% → 50.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 50.2% | +19824.0 pp |
| FY2024 | -19773.9% | -22076.2 pp |
| FY2023 | 2302.4% | +3988.2 pp |
| FY2022 | -1685.9% | +1179.6 pp |
| FY2021 | -2865.5% | +27798.4 pp |
| FY2020 | -30664.0% | -29330.8 pp |
| FY2019 | -1333.1% | -253.8 pp |
| FY2018 | -1079.3% | +1029.3 pp |
| FY2017 | -2108.6% | +7808.1 pp |
| FY2016 | -9916.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Net marginSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating cash flowSPRO Free cash flowSPRO Capital expendituresSPRO Return on equitySPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Total liabilitiesSPRO Shareholders’ equitySPRO overview →